Company Dossier · Health Care
GE HealthCare
- S&P 500
- Nasdaq-100
- Russell 1000
What GE HealthCare is doing, read from its filings, its own words and the news, with every figure dated and sourced. Not investment advice: no ratings, no price targets.
Open the full company record in Palanor: guidance, KPIs, ownership, calls, prices →
The latest read
Computed from the data on Oct 22, 2026. Every figure links back to its source in the sections below.
- Revenue over the four quarters to March 31, 2026: $21.0 billion, up 6.0% from a year earlier.SEC EDGAR filings (XBRL)
- Capital expenditure over the four quarters to March 31, 2026: $0.51 billion, up 24% from a year earlier.SEC EDGAR filings (XBRL)
- Share buybacks in the fiscal year to December 31, 2025: $0.20 billion.SEC EDGAR filings (10-K)
- Long-term debt issued in the fiscal year to December 31, 2025: $2.73 billion.SEC EDGAR filings (10-K)
- Latest earnings call or results release (July 29, 2026): sentiment 0.60 on a −1 to +1 scale (mixed), confidence 0.75 of 1.Palanor Discourse
- Guidance in the last 90 days: 0 outlook figures raised, 0 lowered, 5 held.Guidance Ledger (8-K results releases)
- Latest annual report (filed February 4, 2026): 0 risk factors added, 1 removed.Risk Factor Changes (10-K Item 1A)
- Insiders were net buyers in Q2 2026: $6.4 million on the open market.SEC Form 4
- 1,234 institutional managers reported a position at June 30, 2026 (−42 on the quarter before).SEC Form 13F
- H-1B filings certified in Q2 2026: 38 (60 a year earlier).U.S. Department of Labor (OFLC)
Company Posture
How Company Posture is measured →What GE HealthCare is doing, on three axes, from its filings and its own words, as of 2026-10-22. A description, not a rating: Company Posture never says whether to buy.
Expanding ↔ Retrenching
Withheld: 50% of the evidence is readable at this date (needs 60%).
- Capital spending—
- Debt raised—
- Buybacks vs capex—
- Hiring filings27th pct
- Deals and private raises49th pct
- Patent publications51st pct
Confident ↔ Hedging
Mixed
- Call sentiment63rd pct
- Call confidence57th pct
- Guidance changes41st pct
- Risk factors added74th pct
- Insider open-market trades87th pct
- + Insider open-market trades
- + Risk factors added
- + Call sentiment
Pressure
Components only: Not yet shown as a score: in the back-test it did not add to a naive reader's forecast of impairment, debt acceleration or bankruptcy filings (8-K 2.06, 2.04, 1.03) (not enough events (17 in half 1; needs 20)).
- Fails-to-deliver76th pct
- Stress filings48th pct
Credit
How these are built →GE HealthCare's borrowing from its SEC filings: the bonds it priced and the debt on its latest balance sheet. A description, not a rating.
Debt on the balance sheet
$10.2B
- Due within a year $0.0B
- Longer term $10.2B
- Default point $5.1B (short + ½ long)
Finance leases included · Mar 31, 2026 filing
Bonds priced, last 12 months
$1.3B
U.S. dollar tranches with a term sheet on EDGAR. Deals sold under Rule 144A file none and are not counted.
| Priced | Amount | Coupon | Matures | Spread | Yield |
|---|---|---|---|---|---|
| Dec 1, 2025 | $600M | 4.150% | 2028 (3y) | +60bp | 4.150% |
| Dec 1, 2025 | $650M | 4.950% | 2035 (10y) | +95bp | 5.046% |
| Jun 3, 2025 | $650M | 4.800% | 2031 (6y) | +78bp | 4.818% |
| Jun 3, 2025 | $850M | 5.500% | 2035 (10y) | +103bp | 5.500% |
| Aug 7, 2024 | $1B | 4.800% | 2029 (5y) | +103bp | 4.827% |
From the pricing term sheets GE HealthCare filed with the SEC. Spread is to the benchmark Treasury (or Bund, Gilt) at pricing.
Charts
Live charts: each one redraws from today’s data and has an image link to paste into a document or slide.
Capital returned and raised
What the company says
Hiring and ownership
In the news
Headlines that name GE HealthCare, with the publisher and a link. The tone is read from each headline’s own words, never from a summary of the article.
- NeutralGE HealthCare to buy Sofie Biosciences for $945M
Palanor Wire · Oct 6, 2026
- NeutralGE HealthCare to acquire Sofie Biosciences for $945M
BioPharma Dive · Oct 6, 2026
- NeutralGE HealthCare Technologies (GEHC) to Acquire Sofie Biosciences for $945 Million
gurufocus.com · via Marketaux · Oct 5, 2026
- NeutralGE HealthCare in talks over $1bn deal for maker of cancer scan chemicals
FT Companies · Sep 13, 2026
Filings and records
The last two years of notable 8-Ks, offerings, annual reports, federal awards, lobbying reports, patents and other public records, newest first.
- Oct 20, 2026LobbyingLobbying report (RED+BLUE STRATEGIES)third_quarter 2026 · $0.1 million
- Oct 20, 2026LobbyingLobbying report (GE HEALTHCARE TECHNOLOGIES INC.)third_quarter 2026 · $0.3 million
- Oct 20, 2026Patent
- Oct 20, 2026Patent
- Oct 20, 2026Patent
- Oct 20, 2026Patent
- Oct 20, 2026Patent
- Oct 17, 2026LobbyingLobbying report (GUIDEPOSTSTRATEGIES, LLC)third_quarter 2026 · $0.1 million
- Oct 16, 2026LobbyingLobbying report (BALLARD PARTNERS)third_quarter 2026 · $0.1 million
- Sep 22, 20268-KDirector or officer changeItem 5.02
- Aug 18, 20268-KDirector or officer changeItem 5.02
- Jul 23, 20268-KDirector or officer changeItem 5.02
- Jul 20, 2026LobbyingLobbying report (GE HEALTHCARE TECHNOLOGIES INC.)second_quarter 2026 · $0.3 million
- Jul 19, 2026LobbyingLobbying report (GUIDEPOSTSTRATEGIES, LLC)second_quarter 2026 · $0.1 million
- Jul 17, 2026LobbyingLobbying report (RED+BLUE STRATEGIES)second_quarter 2026 · $0.1 million
- Jul 15, 2026LobbyingLobbying report (BALLARD PARTNERS)second_quarter 2026 · $0.1 million
- May 11, 20268-KShareholder vote resultsItem 5.07
- Mar 17, 20268-KDirector or officer changeItem 5.02
- Feb 27, 20268-KMaterial agreement signedItem 1.01
- Feb 27, 20268-KMaterial agreement terminatedItem 1.02
- Feb 4, 202610-KAnnual report (10-K)0 risk factors added, 1 removed
- Dec 15, 20258-KMaterial agreement signedItem 1.01
- Jul 24, 20258-KDirector or officer changeItem 5.02
- May 30, 20258-KShareholder vote resultsItem 5.07
- Mar 31, 20258-KMaterial agreement signedItem 1.01
- Mar 31, 20258-KMaterial agreement terminatedItem 1.02
- Feb 13, 202510-KAnnual report (10-K)0 risk factors added, 18 removed
- Dec 12, 20248-KMaterial agreement signedItem 1.01
- Feb 6, 202410-KAnnual report (10-K)1 risk factors added, 5 removed
Peers
Companies in the same industry in the S&P 500, Russell 1000 or MidCap 400, closest in revenue first. Trailing twelve months, from SEC filings.
| Company | Revenue | Free cash flow | Through |
|---|---|---|---|
| Boston Scientific BSX | $21.0B | $3.6B | Jun 30, 2026 |
| Becton Dickinson BDX | $22.5B | $2.7B | Jun 30, 2026 |
| Stryker Corporation SYK | $25.8B | $4.7B | Jun 30, 2026 |
| Medtronic MDT | $37.5B | $6.1B | Jul 31, 2026 |
| Baxter International BAX | $11.5B | — | Jun 30, 2026 |
| Intuitive Surgical ISRG | $11.0B | $3.2B | Jun 30, 2026 |
| Zimmer Biomet ZBH | $8.5B | $1.5B | Jun 30, 2026 |
| Edwards Lifesciences EW | $6.5B | $1.4B | Jun 30, 2026 |